Podcasts about sarcomas

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine.  Timestamps:     00:00 – Introduction   01:56 – Anti-angiogenic therapies  05:03 – Treatment resistance  07:53 – Genetic polymorphisms  09:02 – Sarcoma treatments  11:16 – Novel drugs  15:22 – Oncology societies  18:00 – Carles' three wishes for healthcare 

Dr. Shannon Westin and her guest, Dr. Breelyn Wilky, discuss the JCO article, "“Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas." TRANSCRIPT  Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth on research that has been published in the Journal of Clinical Oncology. I am your host, Gynecologic Oncologist and Social Media Consultant Editor of the JCO, Shannon Westin. I serve here from the University of Texas MD Anderson Cancer Center. And I am so excited to welcome Dr. Breelyn Wilky. She's an Associate Professor and the Director of Sarcoma Medical Oncology in the Department of Medicine Division of Medical Oncology, and the Cheryl Bennett & McNeilly family endowed chair in Sarcoma Research, the Deputy Associate Director of Clinical research at the University of Colorado Cancer Center. Welcome. Dr. Breelyn Wilky: Thank you so much. I'm delighted to be here. Shannon Westin: And with all those titles, I'm super impressed that she was able to complete the manuscript that we're going to discuss today, which is “Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.” And this was published in the JCO on January 27, 2025. And please note, our participants do not have any conflicts of interest. So this is exciting. Let's first level set. Can you review with us just the current state of sarcoma incidents, survival outcomes, that kind of thing so we all know where we're starting? Dr. Breelyn Wilky: Yes. So, you know, sarcomas are really, I like to call them the black box cancer type. And the big thing is that there's really more than a hundred different kinds of sarcomas, which collectively altogether make up only 1% of adult cancers. And so we talk about these as being bone and soft tissue tumors, but really, the heterogeneity is just incredible. You're talking maybe 10,000 to 12,000 new cases of soft tissue sarcoma per year, which is pretty rare in the grand scheme of things. And the trouble with these is that while you can cure sarcomas if you find them early and they're localized, when they metastasize and spread and are not resectable, we're looking at median overall survivals of really only 12 to 18 months, even, you know, with our best therapies that we have. So, really there's just a dire need for new treatments for this really tough group of diseases. Shannon Westin: Yeah, I agree. I'm a gynecologic oncologist, and we have our little subset of sarcomas that I know there's a little bit out of every one. So I'm really excited to pull this manuscript as one of our podcasts offerings because I think we're all seeing these patients in the clinic and certainly our listeners that have sarcoma or have family members with sarcoma, this is so good to have a real focus on a rare group of tumors that have been a little bit lumped together. Now, with that being said, I know this is such a heterogeneous population, but can you briefly overview a little bit around the standard of care for treatment of recurrent sarcomas? Dr. Breelyn Wilky: We have actually been using the same drugs really since about the 1970s, and up until very recently, nothing had really challenged doxorubicin, the old ‘red devil', like we used to call it. And this has been the mainstay of treatment for metastatic sarcomas and really used across the board. In the GYN literature, for uterine leiomyosarcoma, we did see some promising activity with the combination of doxorubicin and trabectedin coming out of the French group. But, except for that study, no combination therapy or new drug has been proven better in terms of overall survival compared to doxorubicin monotherapy, really over 40, 50 years. So it's definitely a tough situation. Now, we do have other drugs that we use, so most patients will wind up getting doxorubicin-based therapy. There's a couple of other regimens that we'll reach to, like gemcitabine docetaxel. And once you get into the specific subtypes, we have some approvals in liposarcomas and leiomyosarcomas for some other drugs. But really the median progression for survival for most of these regimens is somewhere four to six months. And response rates typically are somewhere like 10%, 15% for most of these. So it's really just a very tough field and a tough group of patients to try to make an impact for. Shannon Westin: So let's talk a little bit more kind of getting focused on what you've studied here. What's been the role of immunotherapy thus far in the treatment of sarcomas maybe prior to this particular study? Dr. Breelyn Wilky: Clearly, we all know that immune therapy has just changed cancer care forever over the last few years for so many different types of cancers and diseases like melanoma and renal cell and lung cancer have just been transformed by checkpoint inhibitors specifically directed against PD-1 or CTLA-4 or both. And so, of course, you know, sarcoma docs we're super excited to try to see if these might potentially have activity in our tumors as well. I never had seen myself in my career getting into immunotherapy until I was able to run an investigator-initiated study during my role in Miami, where we combined pembrolizumab, so PD-1 inhibitor, with axitinib which was a pan-VEGF inhibitor. And lo and behold, like I had patients that I was seeing responses when other treatments, all those chemotherapies I was just talking about had failed. And one of my first patients I treated was about a 60-year-old lady with something called cutaneous angiosarcoma. So this is a blood vessel sarcoma all over her face. And we had treated her with 10 different therapies, all the chemotherapy regimens, targeted therapies, clinical trials, and nothing was working. But I put her on a phase 1 trial with a baby dose of CTLA-4 and this woman had a complete response. And so for me, once I saw it work in even just those couple of patients, like that was nothing that we'd ever seen with our chemotherapy regimens. And so that sort of shifted my career towards really focusing on this, and this is about the time where some of the studies started to come out for sarcomas. And the take home with sarcoma is about 20% of sarcomas have this sort of immune hot physiology. So what that basically means is if you look at gene expression of immune related gene signatures, or you look for infiltrating T-cells, sort of the SWAT team of our immune system, like you can find those in the tumors. And it's sort of evidence that the immune system had some clue for that 20% of patients that this was a foreign tumor and that it should be attacking it and maybe just needed a little help. But globally, about 80% of sarcomas are these immune cold tumors, which means the immune system has no clue that these things are even a threat. And there's almost no immune activation, very, very few antigens. In other cancer types, high neoantigens or tumor antigens help the immune system work better. And so that basically goes with what we've seen with trials of PD-1 or CTLA-4 blockade. About 20% of sarcomas, with some exceptions, can respond. But really 80% across the board, you're stuck, you just can't get them to be recognized. And so that's where I think this data is so interesting is there's some signals of activity in these immune cold tumors which, at least historically with the trials we've done so far, we really haven't seen that with sort of the traditional checkpoints. Shannon Westin: So I think now this is a great time to maybe talk about the study design in general, the eligibility and just give us kind of a run through of that. Dr. Breelyn Wilky: So this trial was a phase 1 trial of a drug called botensilimab, which is a next generation CTLA-4 directed immune modulator. So what makes botensilimab different is that the CTLA-4 end is very similar to other CTLA-4 inhibitors that are out there, but it's been engineered on the back end of the molecule that binds to Fc gamma receptors to basically bind tighter with higher affinity. And what this translates to in laboratory models and increasingly now in patients is it does a better job of priming, of educating our T cells, our, again, these highly intelligent antigen specific cells, but also natural killer cells. It does a better job of sort of educating those. It helps to activate macrophages and other supporting actors in the immune response. And so the idea here is that there's evidence that botensilimab may do a better job at creating new responses in immune cold tumors. The study combined either botensilimab as monotherapy or in combination with a PD-1 inhibitor called balstilimab. And this was all comers, really a variety of tumor types. And to date I think we're close to about 500 patients with a variety of solid tumors that have been accrued to this study, this C-800-01 phase 1 trial. This paper reports on the sarcoma patients that were enrolled as part of this study. And so, again, given what I've told you about sarcomas being really immune cold, we were just so excited to have the opportunity to enroll on a next generation immune therapy for these tumors that really we were running into roadblocks trying to use immunotherapy previously. Shannon Westin: It's a very compelling idea and I'm so excited for you to tell people what you found. I think first things first, it was an early phase trial. So why don't we talk a little bit about the safety of the regimen. Was there anything that you didn't expect? Dr. Breelyn Wilky: Right. So similar to other checkpoint inhibitors, you know, the idea is that these drugs can cause immune mediated toxicities, right? So essentially you're revving up the immune system and it can sometimes get a bit confused and start attacking our normal cells, our normal organs, leading to essentially any number of toxicities of basically head to toe, something can get inflamed and you can develop a toxicity from that. So the key take homes with this particular drug with, botensilimab with balstilimab, we saw colitis was sort of the primary immune mediated toxicity and it was about a third of patients, give or take. It happens and it can be aggressive and needs to be managed aggressively. And you know, one of the things that we learned very quickly taking part in this study is how important it is that as soon as patients start to get diarrhea, immunosuppression gets on board. So steroids, early use of TNF alpha blockade, so infliximab for example, if we jumped on it quickly and we recognized it and we got the patients treated, it would resolve fairly quickly and even some patients could remain on treatment. So I think that was sort of the first take home is “Okay if you get colitis, you treat it fast, you treat it early and you can still have patients not only recover, which essentially everybody recovered from this colitis and then being able to continue on treatment and still have their anti-tumor responses.” So that's the first point. The second thing that was really interesting is part of the engineering of botensilimab on the back end of the molecule, it's been designed to decrease complement binding and it's thought that that triggers some of these other toxicities that we've seen with prior CTLA-4 inhibitors like pneumonitis or hypophysitis. We actually don't see that with botensilimab. So there's sort of this selective toxicity that may reflect the design of the molecule. But overall the treatment was, we didn't see any new safety signals that were outside of what we would expect in class. And colitis was sort of the dominant thing that we had to be ready for and ready to manage. Shannon Westin: We've been doing it for a while now, so we kind of know what to do and we can act quickly and really try to mitigate and avoid some of the major toxicities. So that's great that that was what was reflected in what you found. And then of course I think: What about the efficacy?” Right. This is what we care about as practitioners, as patients. Does it work and are there any subtypes that seem to benefit the most from this combination? Dr. Breelyn Wilky: Right. So for the sarcoma patients, we treated 64 patients and 52 of those patients were evaluable for efficacy. So a decent size group of patients in sarcomas, where, you know, typically our trials are pretty small, they're very rare, but we had 52 evaluable with at least one post baseline scan. So that was our criteria. And basically we saw across all of the patients, and keep in mind, these are heavily pre-treated patients, as you mentioned, so a median of 3 prior lines of therapy, so most of these patients had had chemotherapies and then about 20% had also had prior immunotherapy as well. So PD-1 treatments or so on. The overall response rate by RECIST was 19.2% for all of the evaluable patients. And then with iRECIST, which is sort of that immune adapted response criteria that allows for early pseudo progression, we actually had another patient who did have that. And so that response rate was 21.2%. Overall, we were really excited to see this in a heavily pre-treated group of patients. But what was really exciting to me was when we looked at the subset of patients that had angiosarcoma, that blood vessel tumor I was talking about earlier with my other patient. So angios come in two flavors. One is this sort of cutaneous type, or meaning involving the skin that has a UV signature, a UV damage signature, very similar to melanoma. So these tumors tend to have a high mutation burden. And oftentimes there is a track record that we've seen responses with immunotherapy in cutaneous angiosarcomas. But the other group that we deal with is called visceral angiosarcomas. And so these are totally different biologically. These are often driven by mutations in MYC or KDR amplification, and they arise in organs, so primary breast angiosarcoma, not associated with radiation, or they can arise in the liver or the spleen or an extremity. So these are very, very different tumors, and the visceral ones almost never historically have responded to checkpoint inhibitors. So we had 18 patients with angio split - 9 with cutaneous, 9 with visceral. And we were just blown away because the response rate for that group was 27.8%. And if you looked at the responses between the hot ones and the cold ones, it was almost equal and a little bit better in the visceral. So we had a 33% response rate in visceral angiosarcoma, which is crazy, historically speaking, and about 20% again in the cutaneous angios. So for a disease where visceral angio gets treated with chemotherapy, might respond initially, but then rapidly progresses - like these people go through multiple lines of therapy - to have a third of patients responding, and then some of those responses were durable. Our median duration of response for the study was 21.7 months, which is just nuts for sarcomas where we just don't see those sorts of long term benefits with the drugs that we have. So I think those are kind of the two main things. There were other subtypes that had clinical benefit and responses as well in d-diff liposarcoma, soft tissue leiomyosarcoma, which are again thought to be fairly cold immune subtypes. So just really exciting to kind of see responses we hadn't expected in a very challenging group of tumors. Shannon Westin: We see all these patients and we have patients that respond so well to immunotherapy with other histotypes. And so it's so exciting to see an option for these really hard to treat tumors that our patients struggle with. So this is so, so very exciting. I wanted to make mention, you know, I was really impressed with the amount of translational work you were able to do in this early phase study. So do you want to review just maybe a few of the key findings that you guys discovered? Dr. Breelyn Wilky: It's always great. I'm a translational researcher at heart and we do a lot of immune correlative work. And I think the reason I got so excited about this field to begin with was trying to learn why it works for some patients and why it doesn't work for other patients. So I'm a huge believer in learning from every patient that we can. So it's such a testament to the company, Agenus, who sponsored this trial to invest their time and resources into correlative studies at this phase. It's huge. So we learned a couple of things. IL-6 or interleukin 6 is a cytokine that basically has, in other tumor types, been associated with worse outcomes. And what we were interested in this group is we saw the same thing. And again, sarcomas have very, very little correlative biology that's done. We're really in infancy and understanding the microenvironment and how that milieu balances out in our tumors. So we were really excited to see again that lower peripheral interleukin 6 associated with improved overall survival. So again, kind of sorting out a group of patients that might be immunologically favorable when it comes to this type of therapy. The other thing that's important to know about sarcoma is so the other tumor types are lucky and have PD-L1 expression and the tumor is a biomarker, but we never have PD-L1 expression. We can find it in sarcomas and it can be loosely correlated with a chance of benefit with immunotherapy. But I've had patients respond that were PD-L1 negative, and I've had patients that were loaded with PD-L1 that didn't seem to make a difference. And that's not just in this study. So we saw in this trial a trend towards improved overall survival with PD-L1 expression that wasn't significant, but there was like this trend. And it's really interesting because, again, this is largely a CTLA-4 directed therapy. And so what we wondered is if PD-L1 expression is an index of sort of this underlying potential immunogenicity. And actually PD-1 works very late in the whole immune process. That's really at the very end where you've got the T cell that's facing the tumor cell and it's just activating that T cell that's already grown up and already educated and ready to go. Whereas CTLA-4 is really educating in early immune responses and expanding the T cells that have potential to kill. So I'm interested to look into this in more depth in the future to see if this is actually the biomarker for CTLA-4 directed therapy that we've been looking for, because we really don't have a great sense about that. And then the last piece just to note is that in this trial, like most others, very, very few sarcomas had high mutational burden. Everybody was very low, which reflects the population. And it's just really more encouragement than an immune cold tumor with very crappy neoantigens can still respond to immunotherapy if we get them the right agents. Shannon Westin: Yeah, I mean, I'm taking notes because we have such a struggle with this across the gynecologic tumors. I'm like, “Okay, maybe this is finally it.” So hopefully your work will go on to really inspire us across a number of solid tumors that have been traditionally cold. So, so very exciting. And I would just say for my last question, obviously, congratulations on this successful study. What do you think are the next steps for this combination in sarcomas? Dr. Breelyn Wilky: So, again, just to your point, this trial enrolled a bunch of different subtypes, and sarcomas are not the only immune cold tumor that this combo has looked really promising for, microsatellite stable colorectal cancer, ovarian cancer that was platinum refractory, non-small cell lungs. So I think the future is really bright for immune cold tumors kind of across the board. So, yes, lots of hope for not just sarcomas but in terms of our patients, I just have to be so grateful to Agenus for their interest in a rare disease. Sometimes it's hard to get that interest for a very challenging group of patients that are all heterogeneous, they are not all the same and our big clinical trials are a few hundred patients. It's just a very different environment. But they have been so supportive and involved in making sure that sarcomas are represented in their priorities. So there are ongoing discussions about what the optimal way to explore this further in sarcomas is going to be and I cannot wait to have the official plans in place. But my hope is this will not be the last that we see of these drugs for our patients. Shannon Westin: Well, I support that and my vote is on your side. So, thank you so much again, Dr. Wilky. This time just flew by. This was such a great discussion and I mean, I think it's, again, a testament to your exciting data. And thank you to all of our listeners. This has been JCO After Hours' discussion of “Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas,” published in the JCO on January 27, 2025. So be sure to check out the full manuscript. And we hope that you enjoyed this podcast. And if you want to hear more about research published in the JCO, check this out on our ASCO JCO website or wherever you get your podcasts. Have an awesome day.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Dr. Wilky Disclosures  Consulting or Advisory Role: SpringWorks Therapeutics, Deciphera, Epizyme, Adcendo, Polaris, Boehringer Ingelheim, AADi, InhibRx Research Funding: Exelixis Travel, Accommodations, Expenses: Agenus    

El Diario Oficial de Galicia ha publicado la incorporación de la Asociación de Sarcomas Grupo Asistencial al Consejo Asesor de Pacientes de la Área Sanitaria de Ferrol. Este órgano consultivo, regulado por la Orden de 16 de octubre de 2018, tiene como objetivo facilitar la participación de las asociaciones de pacientes y sus familias en la mejora de la calidad de la atención sanitaria. El Consejo Asesor de Pacientes fue creado en la Área Sanitaria de Ferrol en 2019 con el propósito de agrupar a las distintas asociaciones de pacientes. En sus inicios, estaba compuesto por 19 asociaciones y actualmente cuenta con 25 colectivos. Desde su creación, el Consejo ha mantenido varias reuniones para abordar diversos temas relacionados con la atención sanitari

El Dr. Fernando Aldaco Sarvide del CMN “20 de Noviembre”, ISSSTE en la Ciudad de México, nos habla durante el 7º Taller RISE 2025: Residents In Search of Excellence del Colegio Mexicano de Oncología Médica, sobre sarcomas de tejidos blandos.La realización integral de este evento fue gracias a: AstraZeneca México y Pfizer México.Fecha de grabación: 30 de enero de 2025         Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

El Dr. Jorge Alegría Baños, oncólogo médico de Médica Sur en la Ciudad de México, nos habla durante el 7º Taller RISE 2025: Residents In Search of Excellence del Colegio Mexicano de Oncología Médica, sobre sarcomas óseos: osteosarcoma y sarcoma de Ewing.La realización integral de este evento fue gracias a: AstraZeneca México y Pfizer México.Fecha de grabación: 31 de enero de 2025.         Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

El Dr. Javier Martín Broto, oncólogo médico del Hospital Universitario Fundación Jiménez Díaz en Madrid, España, presenta un resumen de los estudios que considera más relevantes en el ámbito de sarcomas expuestos durante el Congreso de ESMO 2024. EREMIS: estudio fase II que evaluó el uso de regorafenib como terapia de mantenimiento en sarcomas de partes blandas. Este diseño incluyó pacientes que recibieron previamente seis ciclos de quimioterapia basada en doxorrubicina y lograron al menos una estabilización o una respuesta objetiva. GEIS-52: estudio fase II, el cual es parte de una investigación impulsada por el grupo español de investigación en sarcomas que explora la combinación de sunitinib y nivolumab en pacientes con sarcoma de tejidos blandos. C-800-01: estudio fase I que evaluó botensilimab más balstilimab en una de las cohortes de angiosarcomas y sarcomas. Multisarc: estudio fase II/III, aleatorizado de medicina de precisión en sarcomas avanzados de tejidos blandos para la identificación de alteraciones genéticas accionables. Estudio que evalúa lenvatinib frente a placebo en pacientes con tumores del estroma gastrointestinal en progresión, específicamente en aquellos que han progresado después de recibir al menos tratamientos previos con imatinib y sunitinib. Estudio que analiza olverembatinib en tumores del estroma gastrointestinal de tipo wall type con deficiencia de SDH. En este estudio olverembatinib muestra una actividad superior a la observada con regorafenib y sunitinib en términos de supervivencia libre de progresión. AXAGIST: estudio fase II que evalúa la combinación de avelumab (un inhibidor de PD-L1) y axitinib (un inhibidor de VEGFR) en pacientes con tumores del estroma gastrointestinal avanzados o metastásicos que han progresado después de terapias estándar. 1721MO: estudio que evalua la seguridad y eficacia de olutasidenib, un inhibidor de la mutación IDH1, para el tratamiento del condrosarcoma con mutación IDH1 recurrente/recidivante o localmente avanzado o metastásico. MOTION: estudio fase III, aleatorizado, controlado con placebo y doble ciego de vimseltinib (DCC-3014) para el tratamiento del tumor de células gigantes tenosinoviales.     Fecha de grabación: 10 de octubre de 2024.                            Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

Send us a textUnlock the secrets of the ever-evolving oncology landscape as Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson take us through another brilliant OJC update. Craig reviews new sarcoma research and also looks at a mortality comparison study of six high-income Anglophone countries. Kate delves into the exciting advancements in precision oncology, particularly the impacts of on children, adolescents, and young adults. CJ looks at a groundbreaking cohort study from Christchurch, New Zealand, revealing how Faecal Immunochemical Tests (FIT) could revolutionise colonoscopy referrals and optimise healthcare resources.Craig announces his career change, stepping away from clinical practice  to a research-centric career, after many years of dedicated practice and impassioned advocacy for regional and rural patients. His passion for changing the healthcare scene in regional Australia, particularly during the COVID-19 pandemic, shines through as he reflects on the emotional yet rewarding transition. With a focus on enhancing patient care, this episode of The Oncology Journal Club provides a comprehensive look at how precision medicine and innovative research are shaping the future of oncology.For papers, bios and other links visit the Show Notes on our website.For the latest oncology news visit www.oncologynews.com.au.We invite healthcare professionals to join The Oncology Network for free - you'll also receive our free weekly publication The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

In today's episode, we discuss the use of hormone replacement therapy (HRT) and local oestrogen in all types of gynaecological cancer patients. Many women after ovarian, womb, cervical, vulval or vaginal cancers feel that they are left out of the conversation and research as so much emphasis is on the breast cancer community. So, here we are with a laser focus on menopause after gynae cancers and we hope this episode is helpful. We are joined by Mr. Vikram Talaulikar, an associate specialist at the reproductive medicine unit in University College London Hospitals NHS Foundation Trust and hon. associate professor at University College London. He explains that menopause after gynaecological cancer treatment is more challenging because it occurs suddenly and the symptoms are often more severe and persistent. We discuss the data and safety for the use of HRT and local oestrogen for:1) Ovarian cancer2) Endometrial cancer3) Cervical cancer4) Vaginal + Vulval cancerEpisode Highlights:00:00 Intro.13:05 HRT now considered for more cancer patients.14:04 HRT generally safe for most ovarian tumours.19:58 Prefer HRT after 12-24 months post-treatment.22:09 Cervical cancer: treatment options hinge on type.30:24 Post-surgery, vaginal oestrogen often necessary; discussions important.33:32 Research non-hormonal treatments before using vaginal oestrogen.38:39 Ideally see a menopause specialist early after cancer diagnosis.42:34 Sarcomas contraindicate hormone use.44:50 Holistic menopause care includes non-hormonal and local treatments.49:18 Discuss options with GP, oncologist, or nurse specialist.Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub A big thanks to our trusted sponsor, The Better Menopause. I'm excited to share their amazing product, The Better Gut with you. Most women don't realize that gut health and menopause symptoms are intrinsically linked—keeping your gut happy is the foundation for overall health, through all stages of life. The Better Gut is a daily capsule packed with a unique, science-backed probiotic blend designed to survive stomach acid, reach your gut alive and help improve symptoms such as bloating, hot flushes and anxiety. Go check them out - The Better Gut is a big help for many https://thebettermenopause.com/products/better-gut?selling_plan=690396627248

Full article: Safety and Efficacy of Percutaneous Cryoablation for Recurrent or Metastatic Soft Tissue Sarcoma in Adult Patients Morgan McLuckey, MD, discusses an AJR article by Pal et al. exploring outcomes from percutaneous cryoablation performed for local control of treatment-refractory recurrent or metastatic soft-tissue sarcoma in adults.

Host: Darryl S. Chutka, M.D., [@chutkaMD] Guests: Steven I. Robinson, M.B.B.S., and Brittany L. Siontis, M.D. When you think of malignancies, sarcomas don't usually come to mind. They are very uncommon and can occur in numerous locations. In addition, they can be very difficult to diagnose as the symptoms they produce are often very subtle. Approximately 15,000 cases of sarcoma are diagnosed each year in the U.S. and because July is Sarcoma Awareness Month, we're going to do our part to raise awareness of sarcomas. My guests for this podcast include Steven I. Robinson, M.B.B.S. and Brittany L. Siontis, M.D., both from the Department of Oncology at the Mayo Clinic. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

In this week's podcast, we join experts Allison Betof Warner from Stanford Medicine, Amod Sarnaik from Moffitt Cancer Center, and... The post iwCAR-T sessions: cell therapies for melanoma and sarcomas appeared first on VJOncology.

In this episode of The Back Table MSK Podcast, Dr. Alexa Levey discusses the importance of multidisciplinary treatment planning for sarcomas with Dr. Yvette Ho and Dr. Jessica Jones. --- CHECK OUT OUR SPONSOR Stryker Interventional Spine https://www.strykerivs.com --- SYNPOSIS The conversation explores the necessity of a multidisciplinary approach and the challenges associated with managing both osseous and soft tissue sarcomas. Dr. Jones highlights recent advancements in precision medicine, including a novel drug, nirogacesta, for desmoid tumors. Dr. Ho addresses common misconceptions surrounding desmoid tumors, emphasizing their potential for significant tissue destruction, and shares insights from her experience in limb salvage surgery. Dr. Levey discusses the considerations involved in needle biopsy and presents case studies where cryoablation effectively reduced desmoid tumor sizes. The doctors also discuss strategies for managing nociceptive and mechanical pain, such as intrathecal pain pumps, radiation therapy, and kyphoplasty. --- TIMESTAMPS 00:00 - Introduction 03:51 - Challenges in Sarcoma Management 13:06 - Precision Medicine in Treatment Planning 16:44 - The Role of Biopsy 20:51 - The Importance of Specialized Oncology Care 25:13 - Collaboration Throughout Treatment Course 31:03 - Cryoablation and Case Studies 35:13 - New Drug Development for Desmoid Tumors 39:06 - Limb Salvage Considerations 41:13 - Metastasis, Recurrence, and Pain Management 49:57 - Final Thoughts --- RESOURCES OGSIVEO (Nirogacestat): https://www.ogsiveo.com/

Follow along with our Nailed it Board/OITE Podcast Companion book. Get your copy by clicking here >> https://a.co/d/cr4i8nD  Enjoy another episode from our board review series featuring Dr. Cole and Dr. Woolwine.   This episode is sponsored by the American Academy of Orthopaedic Surgeons: Filled with content that has been vetted by some of the top names in orthopaedics, the AAOS Resident Orthopaedic Core Knowledge (ROCK) program sets the standard for orthopaedic education. Whether ROCK is incorporated into your residency curriculum, or you use it independently as a study tool, the educational content on ROCK is always free to residents. You'll gain the insights and confidence needed to ensure a successful future as a board-certified surgeon who delivers the best patient care. Log on at https://rock.aaos.org/. 

Follow along with our Nailed it Board/OITE Podcast Companion book. Get your copy by clicking here >> https://a.co/d/cr4i8nD  Enjoy another episode from our board review series featuring Dr. Cole and Dr. Woolwine.   This episode is sponsored by the American Academy of Orthopaedic Surgeons: Filled with content that has been vetted by some of the top names in orthopaedics, the AAOS Resident Orthopaedic Core Knowledge (ROCK) program sets the standard for orthopaedic education. Whether ROCK is incorporated into your residency curriculum, or you use it independently as a study tool, the educational content on ROCK is always free to residents. You'll gain the insights and confidence needed to ensure a successful future as a board-certified surgeon who delivers the best patient care. Log on at https://rock.aaos.org/. 

Follow along with our Nailed it Board/OITE Podcast Companion book. Get your copy by clicking here >> https://a.co/d/cr4i8nD  Enjoy another episode from our board review series featuring Dr. Cole and Dr. Woolwine.   This episode is sponsored by the American Academy of Orthopaedic Surgeons: Filled with content that has been vetted by some of the top names in orthopaedics, the AAOS Resident Orthopaedic Core Knowledge (ROCK) program sets the standard for orthopaedic education. Whether ROCK is incorporated into your residency curriculum, or you use it independently as a study tool, the educational content on ROCK is always free to residents. You'll gain the insights and confidence needed to ensure a successful future as a board-certified surgeon who delivers the best patient care. Log on at https://rock.aaos.org/. 

Commentary by Dr. Vivek Narayan

El Dr. Rodrigo Fernando Riera Sala, oncólogo médico de la Ciudad de México, México, nos acompaña en este video para explorar a fondo sobre los desafíos y avances en el manejo de los sarcomas óseos en el marco del evento RISE 2024, celebrado del 1 al 3 de febrero del presente año.   Fecha de grabación: 02 de febrero 2024 Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

“Lo que da los buenos resultados es la frecuencia con la que realizas una intervención por eso es tan importante que los que nos dirigen concentren este tipo de patología en muy pocos centros”. 

No mais novo episódio da série Dia a Dia, os Drs. Eduardo Sadao Yonamine, Andre Mathias Baptista e Tomás Mansur falam sobre faculdades e o futuro do tratamento da oncologia em sarcomas.

Neste episódio, a Dra. Veridiana Camargo, oncologista clínica da BP – A Beneficência Portuguesa de São Paulo, e o Dr. Antonio C. Buzaid, editor do MOC, comentam os destaques na área de Sarcomas, Melanoma e Pele não Melanoma do congresso da sociedade europeia de oncologia clínica (ESMO 2023), realizado entre os dias 20 e 24 de outubro de 2023. Confira também a aula completa em vídeo no site do MOC.

In this episode, Jonathan is joined by Brian Van Tine, Professor of Medicine in medical oncology and Professor of Paediatrics at the Washington University School of Medicine (WUSM) in St. Louis, Missouri, USA, to provide an overview of his clinical interest in soft tissue and bone sarcomas. The pair explore immunotherapy, specifically monoclonal antibodies and immune checkpoint blockade, and further dive into metabolomics and its relevance to oncology.   Use the following timestamps to navigate the content in this episode:  (00:00)-Introduction  (03:50)-Brian's inspiration for pursuing oncology  (04:43)-The rare tumour world and sarcomas  (06:13)-Immunotherapy trials (09:21)-Treatment options for advanced alveolar soft part sarcoma  (13:52)-Genetic mutations in malignant diseases  (17:13)-Argininosuccinate synthetase 1 (22:49)-Metabolomics (25:55)-Anthracycline-associated cardiotoxicity in patients with soft tissue sarcoma  (28:40)-Treatments available for soft tissue tumours  (31:49)-Three wishes

Matteo Trucco, MD and Kurt Weiss, MD joins us on OsteoBites to describe the collaboration that led to the current Phase 1 clinical trial repurposing the alcoholism drug disulfiram to see if it can overcome the chemotherapy resistance seen in relapsed sarcomas, including osteosarcoma. Matteo Trucco is a Pediatric Oncologist and the Clinical Director of Pediatric Hematology/Oncology at Cleveland Clinic Children's, specializing in the care of children, teenagers and young adults battling bone and soft tissue cancers. He also directs the Children's Cancer Innovative Therapy Program where he and colleagues design, develop and conduct clinical trials seeking more effective and less toxic treatments for childhood cancers. Dr. Trucco earned his undergraduate degree from the University of Pennsylvania and Medical Degree from Temple University School of Medicine. He completed his Pediatrics Residency at Rainbow Babies and Children's Hospital and his Pediatric Hematology/Oncology Fellowship from Johns Hopkins and the National Cancer Institute. In addition to his roles at the Cleveland Clinic, he is a Co-chair of the National Pediatric Cancer Foundation's Sunshine Project consortium, partnering with other top pediatric cancer centers to develop clinical trials. He is honored to be on the Board of MIB Agents, chairs its Scientific Advisory Board and co-chairs the organizing committee for the FACTOR Conference. He also has the privilege of moderating the MIB Agents TURBO Tumor Review Board for Osteosarcoma. Dr. Weiss directs the Department's Musculoskeletal Oncology Laboratory, a basic science laboratory dedicated to the study of sarcomas. His mission is to help develop a world-class translational sarcoma research program at the University of Pittsburgh. As a bone cancer survivor himself, Dr. Weiss brings passion and enthusiasm to the laboratory, clinic, and operating room. Through the UPMC Hillman Cancer Center, he is also a proud collaborator with scientists who are trying to understand how other forms of cancer spread to and destroy the bone. Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sarcoma, Cancer Research, International Journal of Cancer, and others. He is a former member of the NIH's Center for Scientific Review Early Career Reviewer program. He has served on multiple National Cancer Institute Study Sections. He is a member of the Musculoskeletal Tumor Society (MSTS) for which he serves as Chair of the Research Committee and the Connective Tissue Oncology Society (CTOS), for which he has served on the Board of Directors. ----- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Sarcomas are cancers of the connective tissues, with more than 15,000 new cases and 7000 deaths in the US every year. Sarcomas are often diagnosed when they're too late to treat effectively, leading to poor outcomes. As Sarcoma Awareness Month 2023 concludes, Dr. James C. Wittig (Medical Director, Orthopedic Oncology, Atlantic Health System) joins CareTalk to discuss the importance of educating the public about sarcoma cancers.ABOUT CARETALKCareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (President U.S. Healthcare and EVP, Walgreens Boots Alliance) and David Williams (President, Health Business Group) as they debate the latest in US healthcare news, business and policy.ABOUT JAMES C. WITTIG, MDJames C. Wittig is Chairman of Orthopedic Surgery at Morristown Medical Center and Medical Director, Orthopedic Surgery, Orthopedic Oncology and Sarcoma Surgery at Atlantic Health System. GET IN TOUCHBecome a CareTalk sponsorGuest appearance requestsVisit us on the webSubscribe to the CareTalk NewsletterShop official CareTalk merchFOLLOW CARETALKSpotifyApple PodcastsGoogle PodcastsFollow us on LinkedIn#sarcoma #cancer #oncology #healthcare #healthcarenews #healthcarepolicy #medicine #hospitals #doctors #surgeons #healthcareinnovation #healthcarebusinessCareTalk: Healthcare. Unfiltered. is produced by Grippi Media

July is Sarcoma and Bone Cancer Awareness Month. Sarcomas are rare cancers in which malignant cells form in the bones or soft tissues. In this CAPcast, Mary Edgerton, MD sits down with Julie Fanburg-Smith, MD to talk about bone and soft tissue tumors and how the Cancer Protocols support patient care and treatment. Dr. Edgerton is the chair of the Pathology Electronic Reporting Committee and Dr. Fanburg-Smith is a member of the Cancer Committee. More information about the CAP Cancer Protocols: https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocols. For questions, please email us at CancerProtocols@cap.org.

Dr. Maureen Griffin, Dr. Bernard Seguin, and Dr. Brandan Wustefeld-Janssens, authors of "Grade shifts in recurrent canine soft tissue sarcomas and mast cell tumors in: Journal of the American Veterinary Medical Association - Ahead of print (avma.org)" discuss grade shift for recurrent canine STS and MCT. Hosted by Associate Editor Dr. Sarah Wright and Editor-in-Chief Dr. Lisa Fortier.INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA OR AJVR?JAVMA: https://avma.org/JAVMAAuthorsAJVR: https://avma.org/AJVRAuthorsFOLLOW US:JAVMA:Facebook: Journal of the American Veterinary Medical Association - JAVMA | FacebookInstagram: JAVMA (@avma_javma) • Instagram photos and videosTwitter: JAVMA (@AVMAJAVMA) / Twitter AJVR: Facebook: American Journal of Veterinary Research - AJVR | FacebookInstagram: AJVR (@ajvroa) • Instagram photos and videosTwitter: AJVR (@AJVROA) / TwitterJAVMA and AJVR LinkedIn: https://linkedin.com/company/avma-journals#VeterinaryVertexPodcast #JAVMA #AJVRINTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

This week's episode is part 2 of our series in honor of Sarcoma Awareness Month. We will be focusing on Bone sarcomas. We will go over the important details on diagnosis, staging, subtypes and treatment of a few highly testable bone sarcomas. 

Since July is Sarcoma Awareness Month, we are starting a 2-part series on sarcomas. This week's episode will be focusing on soft tissue sarcomas. We will go over the important details on the diagnosis, subtypes and treatment of a few of the highly testable soft tissue sarcomas.

On this episode of Butts and Guts, Dr. Daniel Joyce joins the podcast to discuss gastrointestinal stromal tumors (GISTs) and other sarcomas of the digestive system. Listen to learn about where sarcomas can appear in the digestive system, what causes them to form, the treatment options available, and more.

Video Link --> https://youtu.be/hgnq4zy1ivEZone3Podcast and the gang happy to be joined by Dr. Joanna Shechtel, MD. Dr Shechtel earned her medical degree from Georgetown University. She completed a residency in Diagnostic Radiology at University of Tennessee - Knoxville, where she served as Chief Resident, and a fellowship in Musculoskeletal Imaging at Vanderbilt University Medical Center (VUMC). In 2021, Dr. Shechtel joined VUMC faculty as an Assistant Professor of Clinical Radiology in the Musculoskeletal Radiology section. She is a member of the Radiological Society of North America, American Roentgen Ray Society, American College of Radiology, Tennessee Medical Association and Nashville Academy of Medicine. Dr. Shechtel's clinical interests include MRI safety, quality improvement and resident education. Dr. Shechtel main area of expertise is sarcomas as it pertains to MSK Diagnostic Imaging. Sarcomas are rare cancers that develop in the bones and soft tissues, including fat, muscles, blood vessels, nerves, deep skin tissues and fibrous tissues. There are many risk factors for sarcomas. History of radiation therapy, genetic predisposition and chemical exposure. Imaging properties include size, adjacent tissue differences, infiltrating and contrast enhancement. She was first introduced to the importance of MRI safety by Dr. Peter Petruzzi, MRMD during her residency. She credits Dr. Shellock for her choice to later become a board member of ABMRS.Many factors to consider for sarcoma imaging. coils, image planes, patient positioning, FOV, phase direction, technique, sequence selection etc. Dr. Shechtel doesn't have a preference in field strength if imaging quality isn't compromised. Duplicating a prior study is also a consideration and should be the goal absent of contraindication. High resolution imaging is her preference over small FOV imaging if forced to decide between the two. She stresses the importance of Surgeon preference consideration with joint-to-joint imaging. Prothesis may be in that patient's course of care. Large FOV imaging allows for pre-op measurements as well as visualization of skip lesions. We always love it when our guests come prepared with helpful visual aids. Dr. Shechtel brings imaging examples which help illustrate her case in point. It was a joy spending with someone of Dr. Shechtel's caliber.

Tu perteneces al 10% de las personas en el mundo, que se compromete a conseguir sus deseos y mejorar su vida, eres muy especial, por eso, pon un corazón ❤️ en los comentarios, para sentirme muy feliz de verlo !! Para talleres, cursos y ser avisado de las transmisiones en vivo: Contáctame aquí en whastapp: https://wa.me/message/MLY4PW6JWGG4O1Para ingresar whastapp de manera manual: +52 221 713 0033 Telegram: https://t.me/+GZj5hJM3dsc5ZmJh

What is a soft tissue sarcoma? Soft tissue sarcomas are a broad category of tumors including those that arise from the connective, muscle, or nervous tissues in dogs and cats. These tumors are the result of abnormal production of these cell types in an uncontrolled manner. Connective, muscle, and nervous tissues are present throughout the entire body; therefore, these tumors can develop over the chest, back, side, legs, and facial tissues of your pet. Soft tissue sarcomas make up about 15% of cancers of the skin affecting dogs and about 7% of those affecting cats. Fibrosarcomas are common in dogs and are a type of soft tissue sarcoma (see handout "Fibrosarcoma in Dogs" for more information). "Soft tissue sarcomas make up about 15% of cancers of the skin affecting dogs and about 7% of those affecting cats." Even though soft tissue tumors arise from many different types of cells, they all behave in a similar manner and their treatment is typically the same. What causes soft tissue sarcomas? The reason why a particular pet may develop this, or any tumor or cancer, is not straightforward. Very few tumors and cancers have a single known cause. Most seem to be caused by a complex mix of risk factors, some environmental and some genetic or hereditary. For most cases of soft tissue sarcomas, no direct cause has been determined for their development. Sarcomas at injection sites occur in cats but are rare in dogs (see handout “Post-Vaccination Sarcoma in Cats” for further information on this type of sarcoma). In cats exposed to a form of the feline leukemia virus (called feline sarcoma virus), the development of sarcomas on the head and neck sometimes occurs. What are the clinical signs of soft tissue sarcomas? The clinical signs depend on where the tumor is located and the tissues that are affected. Often, pets have a noticeable mass that is growing in size. Signs associated with soft tissue sarcomas include the following: Pets that have tumors arising from muscle tissue may show signs of pain in the affected region and may have a distinct firm and growing mass (tumor). Tumors that are located on the limbs may cause changes in your pet's ability to walk and the limbs may have obvious swelling. Pets that have tumors arising from nervous tissue may be unable to use the affected limb or may show other neurological signs. Pets with intestinal tumors may have signs of an intestinal blockage, such as vomiting, diarrhea, lack of appetite, weight loss, and abdominal pain. Pets with soft tissue sarcomas in the mouth often have halitosis (bad breath), difficulty eating, loss of appetite, bleeding in the mouth, or obvious tumors in the mouth. Signs of a soft tissue sarcoma affecting the reproductive system depend on the location of the tumor. For example, if the prostate is affected, difficulty with urinating or defecating may be observed. How are soft tissue sarcomas diagnosed? In some cases, a fine needle aspiration (FNA) may be performed. FNA involves taking a small needle with a syringe to suction a sample of cells directly from the tumor and placing them on a microscope slide. A veterinary pathologist then examines the slide under a microscope. If a diagnosis is not confirmed by this method, a biopsy may be needed. A biopsy is a surgical excision of a piece of the tumor. Pieces of the tumor are then examined under the microscope. This is called histopathology. A biopsy is beneficial because it gives an indication as to how aggressive the tumor is and how its treatment should be approached. Staging (searching for potential spread to other locations in the body) may be recommended. This may include blood work, urinalysis, radiographs (X-rays) of the lungs, and possibly an abdominal ultrasound. If any lymph nodes are enlarged or feel abnormal, further sampling may be pursued to determine if any spread is present. "If any lymph nodes are enlarged or feel abnormal, further sampling may be pursued to determine if any spread is present." How do these tumors typically progress? This is entirely dependent on the location and grade of the tumor. Typically, the higher the grade (these tumors are graded from I to III) the more likely that spread is possible. However, one of the biggest concerns with soft tissue sarcomas is their ability to invade the local surrounding tissues. They can almost be described as an 'octopus', where the bulk of the tumor is the head and the microscopic cells that invade the surrounding tissue are like small tentacles. These ‘tentacles' become challenging to treat when managing your pet's tumor, either by surgery or radiation therapy. "...one of the biggest concerns with soft tissue sarcomas is their ability to invade the local surrounding tissues." What are the treatments for these types of tumors? The most commonly pursued treatment for all soft tissue sarcomas is surgery. Because these tumors typically produce ‘tentacles' of abnormal cells, wide margins (the amount of tissue that needs to be removed) must be obtained for the best control of the tumor. If microscopic cells are left behind after surgery, recurrence of the tumor is much more likely. If cells are left behind (determined through histopathology), either a second surgery or a combination of surgery and radiation therapy may be pursued. Chemotherapy is not usually pursued as a primary treatment unless surgery or radiation are not options for your pet based on the tumor size or location. Chemotherapy may be an option after surgery. Metronomic chemotherapy (daily administration of lower doses of chemotherapy rather than traditional schedules) may be recommended. These therapies will be discussed with you if they are relevant to your pet's particular type of sarcoma.

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. --- Benjamin Nacev, MD PhD is a physician-scientist with an interest in sarcoma biology. His work focuses on understanding the causes of sarcomas with a goal of developing new treatments. Dr. Nacev completed his MD and PhD training at the Johns Hopkins University School of Medicine, where he also trained in Internal Medicine. He moved to Memorial Sloan Kettering where he completed his Medical Oncology Fellowship and later joined the faculty before moving to the University of Pittsburgh School of Medicine and the UPMC Hillman Cancer Center. - What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter.

Kate Senkosky, PA-C, discusses with Sam some basics of the evaluation and management of bone lesions. Sarcomas, Carcinomas, metastatic disease - when do we need to make a referral? Kate Senkosky, PA-C also spoke with the PAOS at this year's annual conference. Audio-visual available for purchase for category 1 enduring credit CME at PAOS.org (coming soon to AAPA.org for non-PAOS members).

Kate Senkosky, PA-C, discusses with Sam some basics of the evaluation and management of bone lesions. Sarcomas, Carcinomas, metastatic disease - what might we see in clinic that we need to refer?

While childhood cancer is rare, 1 in every 266 children and adolescents will be diagnosed with cancer by age 20, according to the American Cancer Society. Each September, advocacy groups, health care institutions, patients and families recognize Childhood Cancer Awareness Month to help families who receive a cancer diagnosis.“A lot of people still don't know what to do if a child is diagnosed with cancer or where to go,” explains Dr. Wendy Allen-Rhoades, a Mayo Clinic pediatric hematologist and oncologist. “We want people to know that we know that a cancer diagnosis is scary. We know that it's life-altering. But we also want you to know that there's hope, that we are doing really good things here at Mayo Clinic and elsewhere. And there is hope for a cure, and there is life after childhood cancer.”Dr. Allen-Rhoades says funding is needed for more pediatric cancer research to continue to improve treatments. One area of focus for her has been sarcomas. Sarcoma — the term for a group of cancers that begin in the bones and in the soft or connective tissues — is one of the more common types of childhood cancer. Fortunately, recent treatment advances have increased survival rates. Of children diagnosed with cancer, 84% now survive five years or more. One of the advances in treatment has been improvement in radiation therapy techniques and the use of proton beam therapy to treat pediatric cancers."Radiation therapy works very well for sarcomas," says Dr. Wendy Allen-Rhoades, a Mayo Clinic pediatric hematologist and oncologist. "And the difference between conventional radiation and proton therapy radiation is that our radiation oncologists are able to contour a little bit tighter with proton therapy. Therefore, the surrounding tissue that is normal is spared from some of the side effects. This is really important in children who are growing because we want them to be able to grow normally."In addition to sparing healthy tissue from the effects of radiation, people who must undergo radiation therapy early in life are less likely to have long-term side effects and complications, such as secondary cancers, with proton beam therapy than with conventional radiation therapy.While treatments and cure rates for sarcomas have improved, Dr. Allen-Rhoades hopes for even better results in the future.“Sarcomas have been a tough nut to crack for sure in terms of research and novel innovative therapies,” says Dr. Allen-Rhoades. “We still have a ways to go, but we're doing much, much better than we were 20—30 years ago. But until we can cure everyone, it will never be enough.”On the Mayo Clinic Q&A podcast, Dr. Allen-Rhoades discusses pediatric sarcomas and the importance of funding for research and support of families dealing with pediatric cancer.

Vallerie “Val” Perrault, 32, sclerosing epithelioid fibrosarcoma, Wethersfield, CT, with Dr. Candace Haddox, Physician, Sarcomas, Dana-Farber ● Just days before Christmas last year, Val was diagnosed with a rare and aggressiveform of sarcoma called sclerosing epithelioid fibrosarcoma.● After an emergency room visit due to extreme shortness of breath, it was discoveredthat her entire left lung cavity was filled with fluid. Subsequent CT scans revealed atumor and a biopsy confirmed the diagnosis of sarcoma. Sarcomas are a group ofcancers that begin in the bones and in the soft tissues of the body.● Val underwent two rounds of chemotherapy; however, the cancer did not respond toit. Her treatment team recommended a newer form of cancer therapy known asimmunotherapy. Immunotherapy enables the body's own immune system torecognize and destroy cancer cells. This therapy has helped to keep Val's cancerstable.● Val was referred to Dana-Farber due to the rarity of her cancer.● Val is currently disabled but previously was a yoga teacher, photographer and writer.Sarcoma facts● Sarcoma is a rare cancer that affects the connective tissue in the body. These tumorsare divided into tumors of the bone or soft tissue.● According to the American Cancer Society, there will be an estimated 13,190 newsoft tissue sarcomas will be diagnosed in the United States for 2022.● According to the National Foundation for Cancer Research, sarcoma is a rare cancer,accounting for about 1% of adult cancers.● They are relatively more common among children. Between 1,500 and 1,700children are diagnosed with a bone or soft tissue sarcoma in the U.S. each year. Thismakes up about 15% of cancers in children under the age of 20.● There are 50 different types of soft tissue sarcomas, which can develop in manydifferent locations and tissues within the body.● Sarcoma cancer cells do not respond to regular cell growth, division and deathsignals like healthy cells do. They also don't organize normally. Instead, they grow into a tumor, which may invade surrounding layers of tissue and possibly spread toother organs.● About 50-60% of sarcomas occur in the arms or legs, and other common areasinclude in the head and neck area, the internal organs or the back of the abdominalcavity (retroperitoneum). Dr. Candace Haddox● Dr. Haddox is a medical oncologist focused on the treatment of soft tissue and bonesarcomas. She has a longstanding interest in sarcomas and is passionate aboutidentifying and developing novel, effective therapies for these diseases.● She serves as the sarcoma liaison to the Center for Cancer Therapeutic Innovation(CCTI) which is Dana-Farber's early phase clinical trial group.

Vallerie “Val” Perrault, 32, sclerosing epithelioid fibrosarcoma, Wethersfield, CT, with Dr. Candace Haddox, Physician, Sarcomas, Dana-Farber Matilda "Tilly" Danoff, 3, spinal glioma, Somerville, with parents, Josh and Clare, and sister, Josephine (8) Stephanie Lafontaine, 41, breast cancer, Everett, with Dr. Filipa Lynce, Director, Inflammatory Breast Center, Dana-Farber

Lorna Day's son Sam was diagnosed with Ewing's Sarcoma in 2010 and went through an arduous treatment ordeal that included losing his left leg and right foot to amputation. After Sam's very unfortunate passing in 2016, Lorna set out to help other pediatric cancer patients and their families as she set up her Sam Day Foundation in honor and memory of her beloved son.  As its' core principal, this foundation focuses on trying to fund research for the most difficult pediatric cancers including many of the Sarcomas and Brain Cancer.Nicknamed the "Hope Junkie," Lorna will talk about the many programs that she has initiated through her foundation in the Pacific Northwest, as she strives to accomplish a goal of getting as many people as possible involved  in this Pediatric Cancer fight from that area of the country, and especially in her home state of Oregon. 

Featuring an interview with Dr Mark Agulnik, including the following topics: What we need to know about sarcomas in 2022 (0:00) Currently available targeted therapies for sarcoma (7:57) Novel agents available for patients with sarcoma (17:22) Role of molecular testing in the management of sarcoma (24:36) New developments in therapy for desmoid tumors (30:21) CME information and select publications

Dr Mark Agulnik from City of Hope in Duarte, California, discusses recent therapeutic advances in soft tissue sarcoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySoftTissue22).

Featuring a discussion on recent advances in the treatment of soft tissue sarcoma with Dr Mark Agulnik, moderated by Dr Neil Love.

Featuring a discussion on recent advances in the treatment of soft tissue sarcoma with Dr Mark Agulnik, moderated by Dr Neil Love.

Sarcomas remains a challenging diagnosis for patients and families. Sometimes a dire diagnosis and at difficult times it can be difficult to see what lies ahead. In this Episode we discuss with Dr. Kurt Weiss, Orthopaedic oncology surgeon and sarcoma survivor. Dr. Weiss is simply amazing and we discuss his journey from diagnosis to present, his passions and experience. Find out More about our Doctors: Dr. Izuchukwu Ibe: www.linkedin.com/in/izuchukwu-ibe-a073537a/ Dr. Elyse Brinkmann: www.linkedin.com/in/elyse-brinkmann/ Dr. Weiss: @ndbonedoc (Instagram) https://www.instagram.com/ndbonedoc/ Find out more Pittsburgh University's Ortho Dept. https://www.instagram.com/pittortho/

Meet Dr. Brittany L. Siontis, a medical oncologist with a specialty interest in sarcomas. What are sarcomas? Sarcomas are a rare, insidious, and little-understood cancer that can affect adults and children alike. Often misdiagnosed, sarcomas can begin either in the bones or in the soft tissue. For that reason, they are very difficult to catch in their early stages. Dr Siontis currently serves as the Principal Investigator of several active clinical trials at Mayo Clinic through the Sarcoma Medical Oncology Group and works closely with the non-profit Rein in Sarcoma, a resource for patients and families touched by this disease. In this episode of The Seam Podcast, we sit down with one of the world's leading experts on this cancer to better understand her work within this emerging field of research.The SEAMLynne Cohen FoundationGuest: Dr. Brittany L. Siontis Hosted on Acast. See acast.com/privacy for more information.

Comprehensive, relevant and insightful conversations about health and medicine happen here… on MedStar Health DocTalk. … real conversations with physician experts from around the largest healthcare system in the Maryland-DC region.It takes as much as 1200 to 1800 pounds of pressure to break the human thigh bone. But an unexpected snap of that bone could be the first sign of the one cancer we don't talk enough about: sarcomas, or - bone cancer.  Dr. Albert Aboulafia, head of the Division of Orthopedic Oncology for MedStar Health in Baltimore AND medical director of the Weinberg Cancer Institute at MedStar Franklin Square Medical Center, shares information on bone tumors known as Osteosarcoma. 

Drs. Andrew Heller and Marisa Brunetti continue with their 4th episode in their 6 part series on the topic of vaccinology. In this episode, they discuss feline injection site sarcomas. AAHA Standards: https://www.aaha.org/aaha-guidelines/vaccination-canine-configuration/vaccination-canine/ WSAVA Standards: https://wsava.org/global-guidelines/vaccination-guidelines/

Roman Groisberg, MD, Medical Oncologist and Director of the Sarcoma Program at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, discusses treatment options available for different sarcomas.

Roman Groisberg, MD, Medical Oncologist and Director of the Sarcoma Program at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, gives an overview of sarcomas.

Dr. Michael Douvas is an Associate Professor of Medicine in Hematology and Oncology at the University of Virginia School of Medicine. Dr. Douvas received his undergraduate degree in Economics from Princeton University and his MD from the University of Virginia. He completed both his residency in Pediatrics and his fellowship in Adult and Pediatric Hematology/Oncology at the University of North Carolina. Dr. Douvas treats a variety of patients between ages 15-40 for various cancers. He also has been involved in several research publications and clinical trials on leukemia, lymphoma, and sarcoma. Dr. Douvas has been on the Best Doctors in America List from 2013-2020 and took 2nd place for Best Bedside Manner Awards in the OurHealth Charlottesville and Shenandoah Valley Magazine in 2019. Tune in to learn all about sarcomas: bone vs. soft tissue sarcomas, symptoms, diagnoses, treatments, and much more.